Impact of
TNF-i
polymorphisms
psoriatic arthritis
treatment
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
30 Jun 2022
30 Jun 2022
Historique:
received:
08
06
2022
revised:
24
06
2022
accepted:
28
06
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease. The introduction of therapy with biological drugs is promising, even if the efficacy is very variable. Since the response to drugs is a complex trait, identifying genetic factors associated to treatment response could help define new biomarkers for a more effective and personalized therapy. This study aimed to evaluate the potential role of polymorphisms in genes involved in PsA susceptibility as predictors of therapy efficacy. Nine polymorphisms were analyzed in a cohort of 163 PsA patients treated with TNF-i. To evaluate the treatment response, the DAPsA score was estimated for each patient. The possible association between the selected SNPs and mean values of DAPsA differences, at 22 and 54 weeks from the beginning of the treatment, were evaluated by
Identifiants
pubmed: 35887591
pii: jpm12071094
doi: 10.3390/jpm12071094
pmc: PMC9319906
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Expert Rev Clin Pharmacol. 2017 Aug;10(8):899-910
pubmed: 28490202
Clin Rheumatol. 2017 Oct;36(10):2253-2260
pubmed: 28762060
Front Immunol. 2021 Jun 11;12:631603
pubmed: 34177886
Pharmacogenomics. 2021 May;22(7):435-445
pubmed: 33887993
Infect Agent Cancer. 2012 Nov 14;7(1):32
pubmed: 23148667
Genes Immun. 2008 Apr;9(3):267-70
pubmed: 18273036
PLoS One. 2014 Nov 04;9(11):e111991
pubmed: 25369137
Indian J Dermatol. 2019 May-Jun;64(3):182-186
pubmed: 31148855
PLoS One. 2015 Nov 16;10(11):e0142683
pubmed: 26569609
Int J Mol Sci. 2021 Mar 08;22(5):
pubmed: 33800290
Pharmacogenomics. 2016 Jun;17(8):943-51
pubmed: 27269419
Ther Adv Musculoskelet Dis. 2021 May 08;13:1759720X211014010
pubmed: 33995606
Pharmacogenomics J. 2016 Jun;16(3):238-42
pubmed: 26149736
Ann Rheum Dis. 2016 Mar;75(3):499-510
pubmed: 26644232
Immunobiology. 2022 May 23;227(4):152232
pubmed: 35642993
Ther Adv Musculoskelet Dis. 2020 Oct 13;12:1759720X20962623
pubmed: 33133245
Curr Rheumatol Rep. 2020 Mar 12;22(4):10
pubmed: 32166449
J Pediatr Gastroenterol Nutr. 2020 Oct;71(4):508-515
pubmed: 32773718
Immunol Rev. 2008 Dec;226:205-18
pubmed: 19161426
J Eur Acad Dermatol Venereol. 2019 Apr;33(4):e175-e177
pubmed: 30653751
J Immunol Res. 2019 Feb 10;2019:7682827
pubmed: 30882006
Nat Rev Rheumatol. 2014 Sep;10(9):531-42
pubmed: 25003762
Front Pharmacol. 2021 Jun 15;12:672515
pubmed: 34211394
PLoS One. 2017 Jan 20;12(1):e0169956
pubmed: 28107378
N Engl J Med. 2007 Sep 6;357(10):977-86
pubmed: 17804842
Clin Exp Rheumatol. 2020 Nov-Dec;38(6):1046-1055
pubmed: 33253102
Nat Rev Rheumatol. 2022 Aug;18(8):465-479
pubmed: 35761070
Nat Immunol. 2013 Jan;14(1):72-81
pubmed: 23202271
Biologics. 2020 Aug 20;14:53-75
pubmed: 32903867
J Invest Dermatol. 2014 Oct;134(10):2503-2509
pubmed: 24594669
Clin Genet. 2018 Mar;93(3):481-497
pubmed: 29194620
Ann Rheum Dis. 2003 Jun;62(6):526-9
pubmed: 12759288
Ann Rheum Dis. 2016 May;75(5):811-8
pubmed: 26269398
PLoS One. 2015 Jun 24;10(6):e0130907
pubmed: 26107717
Front Immunol. 2019 Nov 20;10:2726
pubmed: 31824506
Mol Med. 2008 Sep-Oct;14(9-10):575-81
pubmed: 18615156